Navigation Links
Endocare Comments on Unsolicited Proposal
Date:8/7/2008

IRVINE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- The Board of Directors of Endocare, Inc. (Nasdaq: ENDO) received on August 6, 2008 an unsolicited proposal from HealthTronics, Inc. (Nasdaq: HTRN) to purchase all of the outstanding shares of Endocare common stock for $2.28 per share in cash.

Endocare's Board of Directors, consistent with its fiduciary duties, and in consultation with its financial and legal advisors, will review and consider HealthTronics' unsolicited proposal carefully and promptly in the context of Endocare's strategic plans and pursue the best course of action for the long-term value to stockholders.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Investor Contact: Media Contact: For Additional Information:

Matt Clawson Len Hall Craig T. Davenport, CEO

Allen & Caron, Inc. Allen & Caron, Inc. Michael R. Rodriguez, CFO

(949) 474-4300 (949) 474-4300 Endocare, Inc.

matt@allencaron.com len@allencaron.com (949) 450-5400

http://www.allencaron.com http://www.allencaron.com http://www.endocare.com


'/>"/>
SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Endocare Stock to Commence Trading on NASDAQ
2. Endocare Reports 2007 Third Quarter and Nine-Month Results
3. Endocare Announces That National Cancer Institute to Sponsor Study Comparing Cryoablation to Radiation Therapy for Pain Relief in Bone Cancer Patients
4. Endocare Reports 2007 Annual and Fourth Quarter Financial Results
5. Endocare to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
6. Endocare Reports Financial Results for Second Quarter 2008
7. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
8. QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million
9. The Branded Pharmaceutical Association Comments on Hydrocodone
10. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
11. Pelosi Statement on Stark Comments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... ... and numeral energies can describe personality traits in humans. Using presidential candidate Donald ... their name and vitality. , “AstroNumerology is not about adding numbers up,” ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Interest is on ... screening tool and as an orthogonal tool for RNAi hit validation. A key reason ... specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The ... on New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria ... the country’s “modern medical money maelstrom.” , During the interview with Mr. Feiner ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising Age has ... statement solutions provider, for the tenth consecutive year as a Top 20 Marketing ... Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” category. ...
(Date:5/31/2016)... ... 2016 , ... Super Powder, a supplement produced by Prox Formulas for providing ... athletes, continues to transform the nutritional supplement industry by providing a safe, natural approach ... amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... India , May 27, 2016 ... the instances of hypertension is driving ambulatory blood pressure ... lose their elasticity and their ability to respond to ... pressure. This condition can lead to various cardiovascular disorders ... peripheral vascular disease. These diseases are growing in prevalence ...
(Date:5/27/2016)... 27, 2016 The healthcare sector ... insurance companies all falling under its umbrella.  A rather ... not often talked about, these healthcare companies are still ... is by far the largest consumer of ... Corp. (OTC: ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. ...
Breaking Medicine Technology: